Clinical Trial Update: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial of a fixed-dose combination of Sofosbuvir/Velpatasvir for 12 weeks in adults with chronic hepatitis C virus infection has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir/Velpatasvir Fixed Dose Combination (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-03-19